Federal Bureau of Prisons
Attestation Reviews of DOJ's Fiscal Year 2017 Annual Accounting and Authentication of Drug Control Funds and Related Performance
The OIG is conducting attestation reviews of the Fiscal Year 2017 Annual Accounting of Drug Control Funds and Related Performance of DOJ's Assets Forfeiture Fund, Criminal Division, Drug Enforcement Administration, Federal Bureau of Prisons, Office of Justice Programs, Offices of the United States Attorneys, Organized Crime Drug Enforcement Task Forces, and United States Marshals Service, hereinafter referred to as "the components". Pursuant to 21 U.S.C. § 1703(d)(7), the Office of National Drug Control Policy (ONDCP) issued ONDCP Circular, Accounting of Drug Control Funding and Performance Summary, dated January 18, 2013, which requires the OIG to perform annual reviews of the components' drug control funds and related performance.
Audit of the BOP's Counterterrorism Efforts
The OIG is conducting an audit of the BOP's counterterrorism efforts. The preliminary objectives are to review the BOP’s policies, procedures, and practices for monitoring inmates with known or suspected ties to domestic and foreign terrorism and its efforts to prevent further radicalization among its inmate population.
BOP Contract Awarded to Sealaska Constructors, LLC, to Build Facilities at FCI Danbury
The OIG is conducting an audit of the BOP's contract awarded to Sealaska Constructors, LLC, to construct facilities at a federal correctional institution in Danbury, Connecticut. Our preliminary objective is to assess the BOP’s and Sealaska Constructors, LLC’s compliance with the terms, conditions, laws, and regulations applicable to this contract in the areas of: (1) acquisition planning; (2) contract management, oversight, and monitoring; and (3) billings and payments.
BOP Contracts Awarded to Pacific Forensic Psychology Associates, Inc.
The OIG is auditing BOP contracts awarded to Pacific Forensic Psychology Associates, Inc. The preliminary objective of the audit is to assess the BOP’s administration of the contracts and Pacific Forensic Psychology Associates, Inc.’s performance and compliance with the terms, conditions, laws, and regulations applicable to these contracts. The assessment of performance may include financial management, monitoring, reporting, and progress toward meeting the contracts’ goals and objectives.
BOP’s Management of its Female Inmate Population
The OIG is reviewing the BOP’s management of its female inmate population. As part of this review, the OIG will examine trends in the female inmate population between FY 2012 and FY 2016, the BOP’s implementation of its Management of Female Offenders program statement, and the impact of the 2013 decision to convert Federal Correctional Institution Danbury to a male institution.
Perimeter Security Contract Awarded to DeTekion Security Systems, Inc.
The OIG is conducting an audit of a perimeter security contract awarded by the BOP to DeTekion Security Systems, Inc. The preliminary objectives are to: (1) determine whether the BOP adhered to federal regulations during the contract award and administration processes, (2) assess the adequacy of BOP’s contract oversight, and (3) determine if DeTekion Security Systems, Inc., properly invoiced the government and complied with the terms and conditions of the contract award.
Residential Reentry Center Contracts Awarded to Reynolds & Associates, Inc.
The OIG is auditing three BOP contracts awarded to Reynolds & Associates, Inc., for the RRC located in Washington, D.C. The preliminary objective of the audit is to assess the BOP’s and Reynolds & Associates, Inc.’s, administration and performance of, and their respective compliance with the terms, conditions, laws, and regulations applicable to these contracts.
Review of the Federal Bureau of Prisons' and U.S. Marshals Service's Pharmaceutical Drug Costs for Inmates and Detainees
The OIG is conducting a review of the BOP's and USMS's pharmaceutical drug costs for inmates and detainees. This review will examine the budgetary impact of pharmaceutical drugs on the BOP and USMS, as well as their processes for obtaining pharmaceutical drugs.
To detect and deter waste, fraud, abuse, and misconduct in DOJ programs and personnel, and to promote economy and efficiency in those programs.